J
Jane W. Newburger
Researcher at Boston Children's Hospital
Publications - 582
Citations - 64913
Jane W. Newburger is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Kawasaki disease & Medicine. The author has an hindex of 114, co-authored 515 publications receiving 55331 citations. Previous affiliations of Jane W. Newburger include Brigham and Women's Hospital & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Management of Kawasaki disease in resource-limited settings.
TL;DR: Predictive models using US and Taiwanese epidemiologic data suggest that a large and growing patient population will require ongoing management of coronary artery disease following KD, and the rising number of KD patients with coronary aneurysms may also pose a significant burden on health resources in resource-limited settings.
Journal ArticleDOI
Safety and Efficacy of Warfarin Therapy in Kawasaki Disease
Annette L. Baker,Christina VanderPluym,Kimberly Gauvreau,David Fulton,Sarah D. de Ferranti,Kevin G. Friedman,Jenna Murray,Loren D. Brown,Christopher S. Almond,Margaret Evans-Langhorst,Jane W. Newburger +10 more
TL;DR: Bleeding and clotting complications are common in patients with Kawasaki disease on warfarin and aspirin, with INRs in range only two‐thirds of the time, and future studies should evaluate the use of direct oral anticoagulants in children as an alternative to warfarins.
Journal ArticleDOI
Heart block following stage 1 palliation of hypoplastic left heart syndrome
Douglas Y. Mah,Henry Cheng,Mark E. Alexander,Lynn A. Sleeper,Jane W. Newburger,Pedro J. del Nido,Ravi R. Thiagarajan,Satish Rajagopal +7 more
TL;DR: HB after S1P is rare but heralds a poor outcome, and careful monitoring of these patients is recommended given their significantly increased risks of death and heart transplantation.
Journal ArticleDOI
Kawasaki disease: Medical therapies
TL;DR: Antithrombotic therapies are tailored to the risk of thrombosis, and range from aspirin alone for 4-6 weeks in children without aneurysms to a combination of anticoagulation and antiplatelet therapy for those with giant aneurYSms.
Journal ArticleDOI
Clinical outcome score predicts the need for neurodevelopmental intervention after infant heart surgery
Andrew S. Mackie,Andrew S. Mackie,Gwen Y. Alton,Gwen Y. Alton,Irina Dinu,Ari R. Joffe,Ari R. Joffe,Stephen J. Roth,Jane W. Newburger,Charlene M.T. Robertson,Charlene M.T. Robertson +10 more
TL;DR: Clinical outcome scores of ≥3 were associated with a significantly lower PDI at age 18 to 24 months, and this score may be valuable as an end point when evaluating novel potential therapies for this high-risk population.